| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | BCM; BCMA; CD269; TNFRSF13A |
| WB Predicted band size | 20 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human TNFRSF17 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于TNFRSF17(BCMA)抗体的3篇代表性文献摘要：
---
1. **文献名称**：*Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma*
**作者**：Munshi NC, et al.
**摘要**：该研究报道了靶向BCMA的CAR-T细胞疗法(idecabtagene vicleucel)在复发/难治性多发性骨髓瘤患者中的II期临床试验结果。结果显示73%的患者达到客观缓解，中位无进展生存期为8.8个月，证实了BCMA靶向疗法的显著临床潜力。
2. **文献名称**：*Targeting BCMA with GSK2857916 Antibody-Drug Conjugate in Relapsed Multiple Myeloma*
**作者**：Trudel S, et al.
**摘要**：该研究评估了BCMA靶向抗体药物偶联物(belantamab mafodotin)的疗效和安全性。II期临床试验中，单药治疗使31%的复发/难治患者达到部分缓解以上应答，但角膜毒性为主要副作用，提示需进一步优化剂量。
3. **文献名称**：*A BCMAxCD3 Bispecific Antibody for Multiple Myeloma*
**作者**：Topp MS, et al.
**摘要**：研究开发了一种双特异性抗体(AMG 420)，可同时结合BCMA和T细胞表面CD3.诱导T细胞杀伤多发性骨髓瘤细胞。I期试验显示，在最高剂量组中70%的患者达到完全缓解，但需注意细胞因子释放综合征等毒性。
---
这些文献涵盖了CAR-T、双抗和ADC三类BCMA靶向策略，均发表于2018-2020年间的顶级期刊(NEJM、Blood、Lancet Oncology等)，反映了该领域的核心进展。如需具体DOI或补充文献，可进一步提供。
TNFRSF17. also known as B-cell maturation antigen (BCMA), is a cell surface receptor belonging to the tumor necrosis factor receptor superfamily (TNFRSF). It plays a critical role in B-cell development, survival, and differentiation by binding to its ligands, APRIL (a proliferation-inducing ligand) and BAFF (B-cell activating factor). BCMA is predominantly expressed on plasma cells and mature B lymphocytes, making it a key biomarker for diseases involving plasma cell dysregulation, such as multiple myeloma (MM) and autoimmune disorders.
Antibodies targeting TNFRSF17 have garnered significant attention in therapeutic and diagnostic applications. In oncology, anti-BCMA antibodies are engineered as therapeutic agents, including antibody-drug conjugates (ADCs) and bispecific T-cell engagers (BiTEs), to direct immune cells or cytotoxic payloads toward malignant plasma cells. Notable examples include belantamab mafodotin (an ADC approved for relapsed/refractory MM) and teclistamab (a BiTE in clinical trials). Additionally, BCMA-targeting chimeric antigen receptor (CAR) T-cell therapies have shown remarkable efficacy in MM treatment.
Diagnostically, anti-TNFRSF17 antibodies are used to detect BCMA expression in tissues or serum, aiding in disease monitoring and prognosis. Research also explores their role in modulating immune responses in autoimmune conditions by interrupting BAFF/APRIL-BCMA signaling. Despite promising outcomes, challenges like on-target/off-tumor toxicity and resistance mechanisms remain areas of active investigation. Overall, TNFRSF17 antibodies represent a versatile tool bridging translational research and clinical innovation.
×
